Somu Ravindranadh V, Wilson Daniel J, Bennett Eric M, Boshoff Helena I, Celia Laura, Beck Brian J, Barry Clifton E, Aldrich Courtney C
Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA.
J Med Chem. 2006 Dec 28;49(26):7623-35. doi: 10.1021/jm061068d.
Tuberculosis is the leading cause of infectious disease mortality in the world by a bacterial pathogen. We previously demonstrated that a bisubstrate inhibitor of the adenylation enzyme MbtA, which is responsible for the second step of mycobactin biosynthesis, exhibited potent antitubercular activity. Here we systematically investigate the structure-activity relationships of the bisubstrate inhibitor glycosyl domain resulting in the identification of a carbocyclic analogue that possesses a KIapp value of 2.3 nM and MIC99 values of 1.56 microM against M. tuberculosis H37Rv. The SAR data suggest the intriguing possibility that the bisubstrate inhibitors utilize a transporter for entry across the mycobacterial cell envelope. Additionally, we report improved conditions for the expression of MbtA and biochemical analysis, demonstrating that MbtA follows a random sequential enzyme mechanism for the adenylation half-reaction.
结核病是全球由细菌病原体导致的传染病死亡的主要原因。我们之前证明,负责分枝杆菌素生物合成第二步的腺苷化酶MbtA的双底物抑制剂表现出强大的抗结核活性。在此,我们系统地研究了双底物抑制剂糖基结构域的构效关系,从而鉴定出一种碳环类似物,其对结核分枝杆菌H37Rv的表观抑制常数(KIapp)值为2.3 nM,最低抑菌浓度(MIC99)值为1.56 μM。构效关系(SAR)数据表明了一种有趣的可能性,即双底物抑制剂利用一种转运蛋白穿过分枝杆菌细胞壁。此外,我们报告了MbtA表达和生化分析的优化条件,证明MbtA在腺苷化半反应中遵循随机顺序酶机制。